Paper
1 March 1994 Photodynamic therapy of malignancies with benzoporphyrin derivative monoacid ring A
Julia G. Levy, Elizabeth Waterfield, Anna M. Richter, Claire Smits, Harvey Lui M.D., Luciann Hruza, R. Rox Anderson M.D., Vincent Salvatori
Author Affiliations +
Proceedings Volume 2078, Photodynamic Therapy of Cancer; (1994) https://doi.org/10.1117/12.168659
Event: Europto Biomedical Optics '93, 1993, Budapest, Hungary
Abstract
Benzoporohyrin derivative monoacid ring A (BPD) is a lipophilic photosensitizer with a maximum absorption peak at 690 nm. When liposomally formulated, it distributes in human plasma almost exclusively to the lipoprotein fraction. In experimental animals and humans, it demonstrates good selectivity for tumors as well as other hyperproliferative tissues or cells. In experimental animal tumour models we have found maximum selectivity between tumour and normal surrounding tissue to occur within the first hour following intravenous administration, providing an opportunity for very early PDT following injection. Early clinical trial results from treatment of patients with cutaneous cancerous lesions have shown encouraging efficacy at levels of drug between 0.35 and 0.5 mg/kg. In addition, studies on patients with psoriasis indicate that BPD and light may be used to clear psoriatic plaques.
© (1994) COPYRIGHT Society of Photo-Optical Instrumentation Engineers (SPIE). Downloading of the abstract is permitted for personal use only.
Julia G. Levy, Elizabeth Waterfield, Anna M. Richter, Claire Smits, Harvey Lui M.D., Luciann Hruza, R. Rox Anderson M.D., and Vincent Salvatori "Photodynamic therapy of malignancies with benzoporphyrin derivative monoacid ring A", Proc. SPIE 2078, Photodynamic Therapy of Cancer, (1 March 1994); https://doi.org/10.1117/12.168659
Lens.org Logo
CITATIONS
Cited by 16 scholarly publications.
Advertisement
Advertisement
RIGHTS & PERMISSIONS
Get copyright permission  Get copyright permission on Copyright Marketplace
KEYWORDS
Skin

Tumors

Photodynamic therapy

Plasma

Tissues

Clinical trials

Optical filters

Back to Top